Literature DB >> 24316082

Structural basis for enhanced HIV-1 neutralization by a dimeric immunoglobulin G form of the glycan-recognizing antibody 2G12.

Yunji Wu1, Anthony P West1, Helen J Kim2, Matthew E Thornton1, Andrew B Ward2, Pamela J Bjorkman3.   

Abstract

The human immunoglobulin G (IgG) 2G12 recognizes high-mannose carbohydrates on the HIV type 1 (HIV-1) envelope glycoprotein gp120. Its two antigen-binding fragments (Fabs) are intramolecularly domain exchanged, resulting in a rigid (Fab)2 unit including a third antigen-binding interface not found in antibodies with flexible Fab arms. We determined crystal structures of dimeric 2G12 IgG created by intermolecular domain exchange, which exhibits increased breadth and >50-fold increased neutralization potency compared with monomeric 2G12. The four Fab and two fragment crystalline (Fc) regions of dimeric 2G12 were localized at low resolution in two independent structures, revealing IgG dimers with two (Fab)2 arms analogous to the Fabs of conventional monomeric IgGs. Structures revealed three conformationally distinct dimers, demonstrating flexibility of the (Fab)2-Fc connections that was confirmed by electron microscopy, small-angle X-ray scattering, and binding studies. We conclude that intermolecular domain exchange, flexibility, and bivalent binding to allow avidity effects are responsible for the increased potency and breadth of dimeric 2G12.
Copyright © 2013 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24316082      PMCID: PMC3919625          DOI: 10.1016/j.celrep.2013.11.015

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  61 in total

1.  Stoichiometry of the interaction between the major histocompatibility complex-related Fc receptor and its Fc ligand.

Authors:  L M Sánchez; D M Penny; P J Bjorkman
Journal:  Biochemistry       Date:  1999-07-20       Impact factor: 3.162

2.  Convergent solutions to binding at a protein-protein interface.

Authors:  W L DeLano; M H Ultsch; A M de Vos; J A Wells
Journal:  Science       Date:  2000-02-18       Impact factor: 47.728

Review 3.  Immunoglobulin structure and function as revealed by electron microscopy.

Authors:  K H Roux
Journal:  Int Arch Allergy Immunol       Date:  1999-10       Impact factor: 2.749

4.  gp120: Biologic aspects of structural features.

Authors:  P Poignard; E O Saphire; P W Parren; D R Burton
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

5.  Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo.

Authors:  P Poignard; R Sabbe; G R Picchio; M Wang; R J Gulizia; H Katinger; P W Parren; D E Mosier; D R Burton
Journal:  Immunity       Date:  1999-04       Impact factor: 31.745

6.  Hemagglutinin 1-specific immunoglobulin G and Fab molecules mediate postattachment neutralization of influenza A virus by inhibition of an early fusion event.

Authors:  M J Edwards; N J Dimmock
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

7.  Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design.

Authors:  E O Saphire; P W Parren; R Pantophlet; M B Zwick; G M Morris; P M Rudd; R A Dwek; R L Stanfield; D R Burton; I A Wilson
Journal:  Science       Date:  2001-08-10       Impact factor: 47.728

Review 8.  3D domain swapping: as domains continue to swap.

Authors:  Yanshun Liu; David Eisenberg
Journal:  Protein Sci       Date:  2002-06       Impact factor: 6.725

9.  Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,).

Authors:  A P West; P J Bjorkman
Journal:  Biochemistry       Date:  2000-08-15       Impact factor: 3.162

10.  The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

Authors:  Rogier W Sanders; Miro Venturi; Linnea Schiffner; Roopa Kalyanaraman; Hermann Katinger; Kenneth O Lloyd; Peter D Kwong; John P Moore
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

View more
  19 in total

Review 1.  Next generation antibody drugs: pursuit of the 'high-hanging fruit'.

Authors:  Paul J Carter; Greg A Lazar
Journal:  Nat Rev Drug Discov       Date:  2017-12-01       Impact factor: 84.694

2.  Structure of 2G12 Fab2 in complex with soluble and fully glycosylated HIV-1 Env by negative-stain single-particle electron microscopy.

Authors:  Charles D Murin; Jean-Philippe Julien; Devin Sok; Robyn L Stanfield; Reza Khayat; Albert Cupo; John P Moore; Dennis R Burton; Ian A Wilson; Andrew B Ward
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

3.  Complement is activated by IgG hexamers assembled at the cell surface.

Authors:  Christoph A Diebolder; Frank J Beurskens; Rob N de Jong; Roman I Koning; Kristin Strumane; Margaret A Lindorfer; Marleen Voorhorst; Deniz Ugurlar; Sara Rosati; Albert J R Heck; Jan G J van de Winkel; Ian A Wilson; Abraham J Koster; Ronald P Taylor; Erica Ollmann Saphire; Dennis R Burton; Janine Schuurman; Piet Gros; Paul W H I Parren
Journal:  Science       Date:  2014-03-14       Impact factor: 47.728

4.  Engineering the Human Fc Region Enables Direct Cell Killing by Cancer Glycan-Targeting Antibodies without the Need for Immune Effector Cells or Complement.

Authors:  Mireille Vankemmelbeke; Richard S McIntosh; Jia Xin Chua; Thomas Kirk; Ian Daniels; Marilena Patsalidou; Robert Moss; Tina Parsons; David Scott; Gemma Harris; Judith M Ramage; Ian Spendlove; Lindy G Durrant
Journal:  Cancer Res       Date:  2020-06-12       Impact factor: 12.701

Review 5.  The role of Fc receptors in HIV prevention and therapy.

Authors:  Austin W Boesch; Eric P Brown; Margaret E Ackerman
Journal:  Immunol Rev       Date:  2015-11       Impact factor: 12.988

6.  Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies.

Authors:  Wilton B Williams; R Ryan Meyerhoff; R J Edwards; Hui Li; Kartik Manne; Nathan I Nicely; Rory Henderson; Ye Zhou; Katarzyna Janowska; Katayoun Mansouri; Sophie Gobeil; Tyler Evangelous; Bhavna Hora; Madison Berry; A Yousef Abuahmad; Jordan Sprenz; Margaret Deyton; Victoria Stalls; Megan Kopp; Allen L Hsu; Mario J Borgnia; Guillaume B E Stewart-Jones; Matthew S Lee; Naomi Bronkema; M Anthony Moody; Kevin Wiehe; Todd Bradley; S Munir Alam; Robert J Parks; Andrew Foulger; Thomas Oguin; Gregory D Sempowski; Mattia Bonsignori; Celia C LaBranche; David C Montefiori; Michael Seaman; Sampa Santra; John Perfect; Joseph R Francica; Geoffrey M Lynn; Baptiste Aussedat; William E Walkowicz; Richard Laga; Garnett Kelsoe; Kevin O Saunders; Daniela Fera; Peter D Kwong; Robert A Seder; Alberto Bartesaghi; George M Shaw; Priyamvada Acharya; Barton F Haynes
Journal:  Cell       Date:  2021-05-20       Impact factor: 41.582

Review 7.  Antibodies for Human Immunodeficiency Virus-1 Cure Strategies.

Authors:  Evan Rossignol; Galit Alter; Boris Julg
Journal:  J Infect Dis       Date:  2021-02-15       Impact factor: 5.226

Review 8.  Structural insights on the role of antibodies in HIV-1 vaccine and therapy.

Authors:  Anthony P West; Louise Scharf; Johannes F Scheid; Florian Klein; Pamela J Bjorkman; Michel C Nussenzweig
Journal:  Cell       Date:  2014-02-13       Impact factor: 41.582

Review 9.  Glycans in Virus-Host Interactions: A Structural Perspective.

Authors:  Nathaniel L Miller; Thomas Clark; Rahul Raman; Ram Sasisekharan
Journal:  Front Mol Biosci       Date:  2021-06-07

Review 10.  HIV-1 Envelope Conformation, Allostery, and Dynamics.

Authors:  Ashley Lauren Bennett; Rory Henderson
Journal:  Viruses       Date:  2021-05-07       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.